(Q33165430)

English

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 July 2017

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial (English)

1 reference

Europe PubMed Central

23 July 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

triple-negative breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Xi-Chun Hu

1

1 reference

Europe PubMed Central

23 July 2017

Jian Zhang

2

1 reference

Europe PubMed Central

23 July 2017

Bing-He Xu

3

1 reference

Europe PubMed Central

23 July 2017

Li Cai

4

1 reference

Europe PubMed Central

23 July 2017

Joseph Ragaz

5

1 reference

Europe PubMed Central

23 July 2017

Zhong-Hua Wang

6

1 reference

Europe PubMed Central

23 July 2017

Bi-Yun Wang

7

1 reference

Europe PubMed Central

23 July 2017

Yue-E Teng

8

1 reference

Europe PubMed Central

23 July 2017

Zhong-Sheng Tong

9

1 reference

Europe PubMed Central

23 July 2017

Yue-Yin Pan

10

1 reference

Europe PubMed Central

23 July 2017

Yong-Mei Yin

11

1 reference

Europe PubMed Central

23 July 2017

Chang-Ping Wu

12

1 reference

Europe PubMed Central

23 July 2017

Ze-Fei Jiang

13

1 reference

Europe PubMed Central

23 July 2017

Xiao-Jia Wang

14

1 reference

Europe PubMed Central

23 July 2017

Gu-Yin Lou

15

1 reference

Europe PubMed Central

23 July 2017

Dong-Geng Liu

16

1 reference

Europe PubMed Central

23 July 2017

Ji-Feng Feng

17

1 reference

Europe PubMed Central

23 July 2017

Jian-Feng Luo

18

1 reference

Europe PubMed Central

23 July 2017

Kang Sun

19

1 reference

Europe PubMed Central

23 July 2017

Ya-Jia Gu

20

1 reference

Europe PubMed Central

23 July 2017

Jiong Wu

21

1 reference

Europe PubMed Central

23 July 2017

Zhi-Min Shao

22

1 reference

Europe PubMed Central

23 July 2017

publication date

18 March 2015

1 reference

Europe PubMed Central

23 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

23 July 2017

16

1 reference

Europe PubMed Central

23 July 2017

4

1 reference

Europe PubMed Central

23 July 2017

436-446

1 reference

Europe PubMed Central

23 July 2017

Triple-Negative Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting triple-negative breast cancer: optimising therapeutic outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized clinical trial design for assessing noninferiority when superiority is expected

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Decision-theoretic views on simultaneous testing of superiority and noninferiority

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

BRCA1/2 mutations and triple negative breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970064-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)70064-1

1 reference

Europe PubMed Central

23 July 2017

1 reference

Europe PubMed Central

23 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33165430&oldid=1974435098"